Title: Evaluation of cardiolipin nanodisks as lipid replacement therapy for Barth syndrome
Authors: Nikita Ikon1, Fong-Fu Hsu2, Jennifer Shearer1, Trudy M. Forte1, Robert O. Ryan1,3
Institutions: 1Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA; 2Department of Medicine, School of Medicine, Washington University, St. Louis, MO 63110, USA; 3Department of Biochemistry, University of Nevada, Reno, NV 89557, USA.
Abstract: Barth syndrome (BTHS) is a mitochondrial disorder characterized by cardiomyopathy and skeletal muscle weakness. Disease results from mutations in the tafazzin (TAZ) gene, encoding a phospholipid transacylase. Defective tafazzin activity results in an aberrant cardiolipin (CL) profile. The feasibility of restoring the intracellular CL profile was tested by in vivo administration of exogenous CL in nanodisk (ND) delivery particles. Ninety mg/kg CL (as ND) was administered to doxycycline-inducible taz shRNA knockdown (KD) mice once a week. After 10 weeks of CL-ND treatment, the mice were sacrificed and tissues harvested. Liquid chromatography-mass spectrometry of extracted lipids revealed that CL-ND administration failed to alter the CL profile of taz KD or WT mice. Thus, although CL-ND were previously shown to be an effective means of delivering CL to cultured cells, this effect does not extend to an in vivo setting. We conclude that CL-ND administration is not a suitable therapy option for BTHS.
Keywords: mitochondria, cardiomyopathy, nanoparticles, drug delivery
Full Text: JBR-2017-0094.pdf
J Biomed Res published on 17 December 2017, https://doi.org/10.7555/JBR.32.20170094